Incorporation of doxorubicin into plant-derived nanovesicles: process monitoring and activity assessment.

IF 6.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Delivery Pub Date : 2025-12-01 Epub Date: 2024-12-11 DOI:10.1080/10717544.2024.2439272

Aleksandra Steć, Monika Targońska, Shishir Jaikishan, Rui Chen, Piotr Mucha, Grzegorz S Czyrski, Jacek Jasiecki, Agata Płoska, Andrea Heinz, Susanne K Wiedmer, Leszek Kalinowski, Krzysztof Waleron, Bartosz Wielgomas, Szymon Dziomba

{"title":"Incorporation of doxorubicin into plant-derived nanovesicles: process monitoring and activity assessment.","authors":"Aleksandra Steć, Monika Targońska, Shishir Jaikishan, Rui Chen, Piotr Mucha, Grzegorz S Czyrski, Jacek Jasiecki, Agata Płoska, Andrea Heinz, Susanne K Wiedmer, Leszek Kalinowski, Krzysztof Waleron, Bartosz Wielgomas, Szymon Dziomba","doi":"10.1080/10717544.2024.2439272","DOIUrl":null,"url":null,"abstract":"Extracellular vesicles (EVs) are an experimental class of drug carriers. Alternative sources of EVs are currently being explored to overcome limitations related to their manufacturing from mesenchymal stem cells. In this work, Citrus limon-derived EVs were tested as carriers for the widely used chemotherapeutic drug - doxorubicin (DOX). Capillary electrophoresis (CE) and nanoplasmonic sensing (NPS) were developed for the quality control of DOX-EV preparations. It was found that the CE method enables simultaneous detection of free and incorporated DOX and allows assessing the stability of the preparations and the drug leakage. NPS, on the other hand, demonstrated that DOX is accumulated in the interfacial region of the carrier. The activity of DOX-loaded EVs was tested on HeLa (cervical cancer cells) and HEK293T (human embryonic kidney cells) cell lines. It was found that DOX incorporation into plant-derived EVs virtually does not affect the drug's cytotoxicity to HeLa cells but significantly decreases DOX activity against HEK293T cell line.","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"32 1","pages":"2439272"},"PeriodicalIF":6.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11639057/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10717544.2024.2439272","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Extracellular vesicles (EVs) are an experimental class of drug carriers. Alternative sources of EVs are currently being explored to overcome limitations related to their manufacturing from mesenchymal stem cells. In this work, Citrus limon-derived EVs were tested as carriers for the widely used chemotherapeutic drug - doxorubicin (DOX). Capillary electrophoresis (CE) and nanoplasmonic sensing (NPS) were developed for the quality control of DOX-EV preparations. It was found that the CE method enables simultaneous detection of free and incorporated DOX and allows assessing the stability of the preparations and the drug leakage. NPS, on the other hand, demonstrated that DOX is accumulated in the interfacial region of the carrier. The activity of DOX-loaded EVs was tested on HeLa (cervical cancer cells) and HEK293T (human embryonic kidney cells) cell lines. It was found that DOX incorporation into plant-derived EVs virtually does not affect the drug's cytotoxicity to HeLa cells but significantly decreases DOX activity against HEK293T cell line.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Delivery 医学-药学

CiteScore

11.80

自引率

5.00%

发文量

250

审稿时长

3.3 months

期刊介绍： Drug Delivery is an open access journal serving the academic and industrial communities with peer reviewed coverage of basic research, development, and application principles of drug delivery and targeting at molecular, cellular, and higher levels. Topics covered include all delivery systems including oral, pulmonary, nasal, parenteral and transdermal, and modes of entry such as controlled release systems; microcapsules, liposomes, vesicles, and macromolecular conjugates; antibody targeting; protein/peptide delivery; DNA, oligonucleotide and siRNA delivery. Papers on drug dosage forms and their optimization will not be considered unless they directly relate to the original drug delivery issues. Published articles present original research and critical reviews.